<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="24672">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02785575</url>
  </required_header>
  <id_info>
    <org_study_id>2015/2210</org_study_id>
    <nct_id>NCT02785575</nct_id>
  </id_info>
  <brief_title>Adjusted Calculation of Heparin and Protamin Dosing and Correlation With Postoperative Bleeding and Transfusions</brief_title>
  <official_title>The Impact of an Adjusted Calculation Model Regarding Heparin and Protamine Dosing on Bleeding and Transfusions After Cardiac Surgery Compared With Standard Dosing: A Randomized Single Blind Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will compare a novel calculation model (HeProCalc AB) with a standard weight-based
      and activated clotting time adjusted calculation for the dosing of Heparin and protamine and
      assess the impact on postoperative bleeding and blood transfusions after cardiac surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During cardiac surgery with cardiopulmonary bypass (CPB), efficient anticoagulation is
      required in order to avoid microscopic clot formation or, in worst case, massive lift
      threatening thrombus formation. Heparin is by far the most common drug used to prevent blood
      from coagulating during CPB. Activated clotting time (ACT) is a point-of-care test of fibrin
      clotting time that has to be well prolonged to initiate safe CPB.

      Following weaning from CPB, heparin is reversed by protamine. Administration of excess doses
      of protamine may have a deleterious effect on coagulation and contribute to postoperative
      bleeding with need of blood transfusions. In connection with CPB management, heparin and
      protamin doses are commonly calculated using body weight and ACT. However, a new
      Heparin-Protamin-Calculation computer program (HeProCalc) has been developed to provide
      patient titrated dosing of both heparin and protamin. However, any benefits regarding
      postoperative bleeding and transfusions has not been thoroughly investigated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative bleeding</measure>
    <time_frame>12 hours after chest closure</time_frame>
    <description>UDPB severe or massive bleeding</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PLATO major or life-threatening bleeding</measure>
    <time_frame>12 hours after chest closure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BART massive bleeding</measure>
    <time_frame>12 hours after chest closure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BARC CABG-related bleeding</measure>
    <time_frame>12 hours after chest closure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative transfusions</measure>
    <time_frame>12 hours after chest closure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cardiac Surgery</condition>
  <condition>Bleeding</condition>
  <condition>Transfusion</condition>
  <condition>Protamine Sulfate</condition>
  <condition>Heparin</condition>
  <arm_group>
    <arm_group_label>HeProCalc</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm receives heparin and protamine doses according to the novel HeProCalc calculation model.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Traditional calculations</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This arm receives heparin and protamine doses according to the standard protocol (using calculations with body weight and ACT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HeProCalc algorithm</intervention_name>
    <description>Heparin and protamine dosage calculated by the algorithm HeProCalc</description>
    <arm_group_label>HeProCalc</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing cardiac surgery with the use of cardiopulmonary bypass

          -  Indication and planned use of heparin and protamine

        Exclusion Criteria:

          -  Inability to leave informed consent or understanding the outline of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jan van der Linden, MD, PhD</last_name>
    <phone>+46851770121</phone>
    <email>jan.vanderlinden@ki.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gunilla Kjellberg, MSc</last_name>
    <phone>+46851770911</phone>
    <email>gunilla.r.kjellberg@karolinska.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>S17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan A van der Linden, MD PhD</last_name>
      <phone>+46851770000</phone>
      <phone_ext>70121</phone_ext>
      <email>jan.vanderlinden@karolinska.se</email>
    </contact>
    <investigator>
      <last_name>Gunilla Kjellberg, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriella Lindvall, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manne Holm, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Kjellberg G, Sartipy U, van der Linden J, Nissborg E, Lindvall G. An Adjusted Calculation Model Allows for Reduced Protamine Doses without Increasing Blood Loss in Cardiac Surgery. Thorac Cardiovasc Surg. 2016 Sep;64(6):487-93. doi: 10.1055/s-0035-1558649. Epub 2015 Aug 13.</citation>
    <PMID>26270199</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 21, 2016</lastchanged_date>
  <firstreceived_date>May 20, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Jan van der Linden</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Protamines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>On a group level in the planned publication. Upon request we will will share de-identified original data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
